GenesisCare will be the first UK-based provider to bring Lunit’s innovative mammogram AI software into clinical use, helping clinicians identify subtle early changes in mammogram images which may be invisible to the human eye.
The partnership and investment mark an important step towards AI-enhanced breast cancer screening. Automatic breast density scoring and lesion detection will support clinicians’ assessment of mammograms, with the aim of supporting earlier diagnosis, fewer unnecessary callbacks and biopsies, and faster access to the right treatment when cancer is found.
Patients attending breast screening at GenesisCare, the UK’s leading cancer care provider, will soon benefit from clinically validated AI technology that supports radiologists in two key areas: automatic breast density scoring and lesion detection, identifying suspicious areas that may indicate cancer. These capabilities provide additional information to support confident, consistent mammogram interpretation. Evidence from real-world use of Lunit INSIGHT Breast Suite has shown a 13.8% increase in cancers detected in screening images1, alongside reductions in recall rates and false positives2, helping more patients receive answers sooner while avoiding unnecessary follow-up appointments where possible.
Dr Fleur Kilburn-Toppin, GenesisCare’s Specialist Advisor for Breast Radiology, said: “This is a significant development for our patients. Mammograms can reveal very early signs of breast cancer, but some changes are extremely small, subtle or difficult to distinguish, particularly in dense breast tissue. Automatic breast density scoring gives us additional information to inform assessment, while AI-supported lesion detection highlights suspicious areas for closer review. Together, these tools support our interpretation of mammograms and our ability to detect cancer earlier.
“For patients, that means greater reassurance that their mammogram has been carried out to a consistently high standard, reviewed with the support of advanced technology and assessed by experienced specialists. Earlier diagnosis can make an enormous difference. When breast cancer is found at an earlier stage, patients may have more treatment options, less intensive treatment and better outcomes. Just as importantly, improving accuracy can help reduce unnecessary callbacks and biopsies, which can cause significant stress and worry for patients and their families.”
Developed by medical imaging software innovator Lunit, the INSIGHT Breast Suite AI technology supports radiologists with image interpretation by identifying suspicious areas and providing malignancy likelihood scoring. Lunit’s breast AI has been extensively evaluated in international clinical studies, is CE-marked under EU Medical Device Regulations, and FDA-cleared for clinical use. While AI enhances insight and efficiency, every mammogram at GenesisCare will continue to be reviewed by two experienced radiologists, with all decisions remaining firmly clinician-led.
The AI tool will also automatically provide a breast density score, giving clinicians a consistent assessment of the amount of dense tissue visible on each mammogram. This matters because dense breast tissue can make cancers harder to detect on mammograms and is associated with a higher risk of developing breast cancer. Understanding breast density helps clinicians assess a patient’s individual risk and consider whether additional imaging may be appropriate.
Jaemin Oh, General Manager - Europe, Middle East and Asia, Lunit International, said: “Lunit INSIGHT Breast Suite supports breast imaging teams through automatic breast density scoring and lesion detection. By assessing breast density and highlighting suspicious areas for clinicians to review, it provides additional insight to support more accurate assessment, including in dense breasts, while helping to reduce unnecessary callbacks. We are honoured to work with GenesisCare to bring this advanced AI review to UK patients.”
This investment reflects GenesisCare’s commitment to responsibly adopting innovation that directly improves patient care. By combining advanced AI with specialist clinical expertise, GenesisCare is helping patients benefit from consistently high-quality imaging, more accurate screening, earlier diagnosis, fewer unnecessary investigations and the best possible chance of improved outcomes. For more information on GenesisCare advanced cancer care, visit Private Cancer Care, Diagnosis and Treatment | GenesisCare UK.
References:
- Chang, YW, et al., Artificial intelligence for breast cancer screening in mammography (AI-STREAM): preliminary analysis of a prospective multicenter cohort study. Nat Commun 16, 2248 (2025).
- Kwon, Mr., Chang, Y., Ham, SY. et al. Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection. Breast Cancer Res 26, 68 (2024)
###
About GenesisCare
GenesisCare UK is the UK’s leading cancer care provider, specialising in the treatment of complex cancers and transforming cancer care with advanced diagnostics, medical oncology, radiotherapy and theranostics. Operating 14 specialist outpatient centres, with additional centres opening in Leeds and Royal Tunbridge Wells in 2026 and in Poole, Dorset in 2027, we provide patients with world-class care from the UK's top clinical & healthcare teams, and deliver the most advanced, safe and effective cancer care treatments. With a philosophy of treating the whole patient not just their cancer, we take an integrated approach to cancer care. Our personalised treatment programmes are supported with wellbeing services, and support for patients with treatment-induced menopause, both delivered through our partnership with the charity Penny Brohn UK. We also provide on-site exercise medicine which is proven to deliver improved patient outcomes, and access to sleep improvement resources through our partnership with The Sleep Project. We work with universities and leading clinicians around the world, to research and design new and better ways to treat cancers and have a growing UK clinical trials programme to support bringing new therapies to more patients. Treatments are available for patients with health insurance and those paying for their own care.
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
